Masahito Kotaka

9PUBLICATIONS
72CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 27, 2026
Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

|Aug 20, 2026
Clinical significance of WES-defined ERBB2 amplification in resectable colorectal cancer.

|Mar 25, 2025
A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G).

Nozomu Machida, Takehiro Okumura, Narikazu Boku

|Nov 08, 2024
A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan.

Yoshiaki Nakamura, Kristiyana Kaneva, Christine Lo

|May 05, 2022
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.

Takayuki Yoshino, Eiji Oki, Toshihiro Misumi

|Sep 23, 2020
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.

Masahito Kotaka, Yoji Saito, Takeshi Kato

Pageof 2

Frequent Collaborators

3 joint publications

Takayuki Yoshino

3 joint publications

Eiji Oki

2 joint publications

Saori Mishima

2 joint publications

Dai Manaka